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l.orgAbstract: Fatigue is a symptom whose causes are protean and whose phenotype
physical, mood, and behavioral components. Chronic fatigue syndrome (CFS) is an il
has strong biological underpinnings and no definite etiology. Diagnostic criteria estab
the Centers for Disease Control and Prevention have helped classify CFS as an overlap
behavioral, and biological components. These include the presence of fatigue for mo
months associatedwith a diminution of functional activity and somatic symptoms, and
attributable to a specific diagnosis or disease. Four of the following criteria need to be
sore throat, impaired memory or cognition, unrefreshing sleep, postexertional fatigu
glands, aching stiffmuscles, joint pain, andheadaches.Many researchers haveobserved
shares features in common with other somatic syndromes, including irritable bowel sy
fibromyalgia, and temporomandibular joint dysfunction. Correlations between infla
and infection, augmented sensory processing, abnormalities of neurotransmitters, nerv
factors, low levels of serotonin and norepinephrine, abnormalities of homeostasis of
system, and autonomic dysfunctionmay be hallmarks of CFS. The relative contribution
of these abnormalities to the profound fatigue associated with CFS need to be explore
to better evaluate and treat the syndrome.
PM R 2010;2
HISTORY OF CHRONICALLY FATIGUING ILLNESSES
Individuals have been documented as experiencing fatigue, or exhaustion in certain
stances, since written records have been kept. The earliest medical literature
individuals who are chronically fatigued but have no other identifiable medical o
atric illness that would account for these symptoms, and these individuals h
described by many different labels over the millennia. In 1869, Beard first coined
neurasthenia to describe a condition that occurred from depletion of the central
system’s energy reserves, which Beard attributed to the consequences of aspects o
civilization. Physicians in the Beard school of thought associated neurasthenia
stresses of urbanization and the stress experienced a result of an increasingly com
business environment. Typically, the condition was associated with members of t
class or professionals with sedentary employment. The term neurasthenia has larg
abandoned, and no evidence suggests that this disorder was one of urbanization.
Many other terms for chronic fatiguing illnesses have arisen, inappropriate
attributing the chronic symptoms experienced by patients with these illnesses to th
active infection. For example, terms such as Akureyri disease, Iceland disease, Ro
disease, and Tapanui flu all have been used first to describe specific outbreaks of
with chronic fatiguing illnesses and then used more widely to describe others
demonstrated similar symptoms. These patients, typically affected by severe posti
fatigue, may also experience multifocal pain (including in regions such as the
throat, and neck, which are painful during many acute infections), sleep distu
memory difficulties, and many other somatic symptoms.
In fact, in the United States, the disorder we now commonly refer to as chron
syndrome (CFS) largely came about after a potential epidemic of CFS that occurred in
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415PM&R Vol. 2, Iss. 5, 2010practice of a single internist, Daniel Peterson, in
Village, Nevada, in 1984 [1]. The patients in this stu
extensively evaluated by both the Centers for Disease
and Prevention (CDC) and several academic gro
they were found to have immunological abnormaliti
as evidence of elevated antibodies to a number of
viral pathogens, leading to the theory that there was
viral illness that was causing these symptoms. Howe
extensive subsequent investigations of this group of
as well as many other clusters of patients initially ide
part of an “epidemic” of fatiguing illness, it became
ingly clear that neither this symptom complex nor
munological abnormalities identified were specifi
single epidemic, or single pathogen [2-5].
Other terms have been used to describe patients w
we now call CFS. Some of these inaccurately char
this condition to be the result of a single common p
or ubiquitous organisms, hence, the names chronic
Barr virus (EBV), mycoplasma, or yeast infection
Finally, we will reject the use of terms not supp
pathophysiological evidence, such as myalgic encep
elitis. A recurring problem in the history of this illne
causality has not yet been established but is asserte
basis of cross-sectional studies or without appropr
trol groups. These assertions are almost incorrect
because both the symptom complexes and objective
malities” used to infer cause (eg, immunological, neu
crine, imaging findings) are very common in the
population [9-11].
We prefer the terms CFS and idiopathic chroni
(ICF) because they are descriptive and do not impl
lying etiologies or triggers. Also, these terms are c
with the views held by practitioners who treat these
and researchers who study them that CFS/ICF i
heterogeneous disorder that, like many other chron
cal illnesses (eg, hypertension, diabetes), has a multi
etiologic and pathogenic factors that contribute to th
sion of the syndrome [12,13].
DEFINITION OF CFS AND ICF
A 1994 CDC case definition for CFS requires a
months of persistent fatigue that substantially red
person’s level of activity. In addition, 4 or mor
following symptoms must occur with fatigue in a
period: impaired memory or concentration, sore th
der glands, aching or stiff muscles, multijoint p
headaches, unrefreshing sleep, and postexertiona
[14]. Medical conditions that may explain the p
fatigue as well as a number of psychiatric diagn
eating disorders, psychotic disorders, bipolar disor
ancholic depression, and substance abuse within 2
the onset of fatigue) exclude a patient from the dia
CFS. A notable feature of the CDC case definition is tine
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many nonpsychotic psychiatric disorders are not ex
ary for the diagnosis of CFS. Those who do not
fatigue severity or symptom criteria can be given a d
of ICF.
EPIDEMIOLOGY
Although the case definition for CFS has been in
some time [14], there is an unexplainable difference
findings of older epidemiological studies that sugge
this was a very rare (ie, 1% of the population) disor
newer studies in which the authors all agree that th
in at least 1% to 3% of the population [15]. These d
the newer studies are supported by the 2% to 4% pr
data reported for fibromyalgia (FM), in which on
patients meet criteria for CFS [16-18].
Both the prevalence rates of CFS at 1% to 3% an
5% to 10% are remarkably consistent across many
cultures and countries, including the United States
Kingdom, Australia, Brazil, and Nigeria [19-22]. Th
of a recent study collected relevant demographic, s
and diagnostic data from 33 studies in 21 count
subjects had fatigue lasting 1 to 6 months (prolo
tigue), longer than 6 months (chronic fatigue), or m
nostic criteria for CFS. Data were obtained from
subjects (n  20,845 female; 57%), including from
tion-based studies (n  15,749, 42%), studies in
care (n  19,472, 52%), and secondary or specialis
referral clinics (n  2503, 7%). A 5-factor model o
symptom domains was preferred (“musculoskele
fatigue,” “neurocognitive difficulties,” “inflammation
disturbance/fatigue,” and “mood disturbance”) and w
parable across subject groups and settings [19].
Although the core symptoms and condition are v
ilar across countries and cultures, the likelihood
diagnosed is markedly different in different settings
Early reports from tertiary clinics suggested that CFS
primarily young, white, professionally successful
Women do appear to be 1.5 to 2 times or more likel
CFS in population-based studies, but community
have found that white men and women have a low
CFS compared with Latino, African-American, an
American subjects. These disparate findings sugges
increased prevalence of CFS among white subjects
populations is most likely the result of a disparity att
to health-care access and use.
WHAT ARE THE UNIQUE CHARACTERI
OF THE FATIGUE ASSOCIATED WITH C
There is nothing unique about the fatigue associa
hat CFS, except that it is chronic and severe enough to be
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416 Clauw CHRONIC FATIGUE SYNDROMEfunctionally disabling. The authors of many studi
that multidimensional measures such as the Mul
sional Fatigue Inventory or Multidimensional Asses
Fatigue show that patients with CFS experience im
in all fatigue domains and that no single domain is a
affected that any other in a group of CFS patients
general, although there are individual studies repor
trary findings, self-report measures of baseline fatig
sured in various ways) correlate poorly with object
sures of performance (eg, exercise or cognitive
leading many authors to emphasize that “percep
fatigue seems to be abnormal in subjects with CFS
The few neurophysiologic studies performed likew
gest that there is diminished central activation in
with CFS [30,31].
The best indicator of whether fatigue is associa
CFS rather than another condition is literally in the c
it keeps. In the overwhelming majority of patients w
the fatigue is accompanied by multifocal pain, slee
bances, and/or cognitive difficulties. These symp
encompassed within the 8 “minor” criteria for the C
nosis. Many patients with CFS also experience
nausea, night sweats, a subjective sense of fevers,
dizziness, and intolerance to alcohol and medicatio
OVERLAP WITH OTHER FUNCTIONAL
SOMATIC OR CENTRAL PAIN SYNDRO
Although the core symptom of CFS is fatigue, the 19
criteria for CFS require that a patient experiences 4
(of a possible 8) other chronic symptoms besides f
fulfill these criteria. Five of the eight symptoms req
addition to fatigue are pain-based symptoms (sor
tender glands, aching or stiff muscles, multijoint p
headaches); therefore, it is virtually impossible for
to meet CDC CFS criteria without having pain in at
body region. In fact, most patients with CFS have pr
pain in multiple anatomical regions, especially if
queried about chronic pain over the course of their
In fact, an absence of a history of multiple sites of p
differentiate this particular subset of CFS patients
subset that clearly overlaps with FM, irritable bo
drome (IBS), and chronic headache patients, for ex
FM, IBS, chronic headaches, and other related sy
have an interesting history as well. The terms used to
and label patients with these syndromes are als
historical and at least initially were viewed through
spective of the specialist that sees patients with sym
a particular region of the body or of underlying path
(eg, infectious disease, endocrinology). Thus, an i
disease expert may see a patient and focus on the in
nature of his or her symptoms, rule out active in
and use the label CFS. A physiatrist seeing t
patient may focus on the few most severe regions of port
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and diagnose myofascial pain, whereas a rheum
instead notes that the pain is more widespread
accompanied by inflammation and diagnoses FM
ically, subspecialists have used the descriptive ter
familiar to them given their training and patient
tions most commonly treated.
When researchers question the etiology of syndro
example, that EBV does not cause CFS or autoimm
function does not cause FM, the syndromes often
named. “Chronic EBV syndrome” became CFS w
was shown to not be the causative agent. Fibrositis
FM when it was clear there was no diffuse inflamm
fibrous tissue throughout the body and it was demo
instead to be a result of central pain augmentation c
ized by widespread pain. Spastic colitis similarly bec
temporomandibular joint (TMJ) syndrome became t
mandibular joint disorder (TMJD), and interstitial
well on its way to be renamed painful bladder synd
because of the recognition that central factors rat
peripheral damage or inflammation appear to be dr
pain. Even psychiatrists got into the misnaming ga
terms somatoform disorder and somatization imply
tients have multiple somatic symptoms over the c
their lifetime without any clear “organic” cause. T
also is rapidly losing credibility as it becomes inc
clear that there are in fact objective neurobiologica
pinnings to this spectrum of illness.
There is now unanimity that at least a large s
patients with CFS have a condition that is much broa
just CFS and has been labeled variously, includin
tional somatic syndromes,” “medically unexplaine
toms,” “chronic multisymptom illnesses,” “somatof
orders,” and perhaps most appropriately, “central s
syndromes.” Yunus [32] first showed FM to be a
with tension-type headache, migraine, and IBS; th
designed a Venn diagram in 1984 that emphasized
demiological and clinical overlaps between these sy
and primary dysmenorrhea. This diagram helped
research to search for etiological connections amo
syndromes [32,33]. Hudson and colleagues [34-36]
strated that conditions such as CFS, FM, IBS, a
pain/fatigue syndromes coaggregated in patients an
ilies. In this review, the more recent term central s
syndrome (CSS) as proposed by Yunus is used becau
opinion of the review author, it represents the best
ical term at present.
There is also a clear overlap between the CSS d
and a variety of psychiatric disorders (Table 1). Thi
likely occurs at least in part because the same neuro
ters (albeit in different brain regions) are operative in
atric conditions. The presence of comorbid psychi
turbances is somewhat more common in patients w
seen in tertiary care settings than primary careain [37,38]. Figure 1 demonstrates the overlap among FM, CFS,
psychi
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417PM&R Vol. 2, Iss. 5, 2010and a variety of regional pain syndromes as well as
ric disorders and demonstrates that the common un
pathophysiological mechanism observed in most
with FM, and large subsets of patients with the
syndromes, is central nervous system pain or senso
fication.
Table 1. Clinical entities currently considered par
spectrum of central sensitivity syndrome (CSS)
Clinical Syndromes
Fibromyalgia
Chronic fatigue syndrome (CFS)
Irritable Bowel Syndrome (IBS) and other functional
gastrointestinal disorders
Temporomandibular joint disorder (TMJD)
Restless leg syndrome (RLS) and periodic limb move
sleep (PLMS)
Idiopathic low back pain (LBP)
Multiple chemical sensitivity (MCS)
Primary dysmenorrhea
Headache (tension  migraine, mixed)
Migraine
Interstitial cystitis/chronic prostatitis/painful bladder s
Chronic pelvic pain and endometriosis
Myofascial pain syndrome/regional soft-tissue pain sy
Fibromyalgia
■ 2%-4% of population
■ Defined by widespread 
pain and tenderness
Regional Pain Syndromes
■ Irritable bowel [IBS]
■ Interstitial cystitis/ Painful 
bladder syndrome
■ TMJD
■ Idiopathic low back pain
■ Tension HA
■ Vulvodynia
LBP = low back pain; TMD = temporomandibular disorder
Clauw and Chrousos. Neuroimmunomodulation. 1997;4:1
P
amFigure 1. Overlapat-
ing
nts
er
li-
ETIOLOGY AND PATHOGENESIS OF TH
SYNDROMES
The use of research methods such as epidemiolog
twin studies, experimental pain testing, functional
and modern genetics has led to substantial advanc
derstanding several of these conditions, most not
IBS, TMJD, and CFS. These advances have led to an e
recognition that chronic central pain itself is a “dise
very often co-occurs with chronic fatigue, sleep dist
and memory difficulties, and that many of the un
mechanisms operative in these heretofore “idiop
“functional” syndromes may be similar, no matter
the pain is present throughout the body (eg, in
localized to the low back, the bowel, or the bladder
Furthermore, most investigators believe that the
ological underpinnings of these conditions under
psychiatric construct of “somatization,” at least if it i
that these phenomena are the somatic representatio
chological distress with no “real” pathological basis.
shows a theoretical schema for classifying pain syndr
the basis of their underlying mechanisms. It is imp
recognize that even patients with “peripheral” p
dromes such as osteoarthritis or rheumatoid arth
he
in
e
e
Chronic Fatigue Syndrome (C
■ 1% of population
■ Fatigue and 4 of 8 “minor crite
Somatoform Disorder
■ 4% of population
■ multiple unexplained
symptoms — no “or
findings
 and/or 
sory 
ification
Psychiatric Disorde
■ Major depression
■ OCD
■ Bipolar
■ PTSD
■ GAD
■ Panic attacks.
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418 Clauw CHRONIC FATIGUE SYNDROMEoften have elements of central pain that need to be t
such, which is why this construct has moved wel
simple relevance to functional somatic syndromes.
The current thinking about these overlapping sy
and syndromes is as follows, and will be reviewed i
detail:
● The core symptoms seen in patients with these illn
multifocal pain, fatigue, insomnia, cognitive or
problems, and, in many cases, psychological
[9,39]. Some patients in the population only hav
these symptoms, but more often patients have m
the precise location of the pain, and the seve
quality of the fatigue, changes over time. Thus, i
practice it is useful to evaluate patients with id
fatigue regarding fatigue, pain, and sleep dist
during the course of their lifetime. It may be th
patients have this pattern of symptoms and past d
then they have a FM-like central pain syndrome, a
then other reasons for fatigue must be more
Any combin
in a g
Peripheral
(nociceptive)
  Inflammation or 
mechanical damage in all 
tissues
  NSAID, opioid 
responsive
  Responds to procedures
  Behavioral factors minor
  Classic examples
  Osteoarthritis
  Rheumatoid arthritis
  Cancer pain
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  Res
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● The presence and severity of these symptoms vary acr
lations. All of the diagnostic labels in current use are
degree arbitrary because there is no objective tissue pat
gold standard to which “disease” can be anchored.
● These symptoms and syndromes occur approxim
to 2 times more commonly in women than m
gender difference appears more apparent in clin
ples (especially tertiary care), however, than in pop
based samples [37,38].
● There is a strong familial predisposition to these sy
and illnesses, and studies clearly show that these
symptoms and syndromes are separable from de
and other psychiatric disorders [39-41].
● A variety of biological stressors appear to be ca
either triggering or exacerbating these symptom
nesses, including physical trauma, infections,
trauma, and deployment to war, in addition to so
types of psychological stressors (eg, there was no
in somatic symptoms or worsening of FM after the
on may be present 
n individual
uropathic
 or entrapment of 
l nerves
s to both 
l (NSAIDs, 
Na channel 
) and central 
euroactive 
ds) 
ological therapy
Central
(non-nociceptive
  Characterized by  cen
disturbance in pain 
processing (diffuse 
hyperalgesia)
  Tricyclic, neuroactive
compounds most effe
  Behavioral factors mo
prominent
  Classic examples
  Fibromyalgia
  Irritable bowel 
syndrome
  Tension headache
  Idiopathic low back
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419PM&R Vol. 2, Iss. 5, 2010● Groups of patients with these conditions (eg,
chronic headache, TMJD, CFS) display diffuse hy
sia (increased pain in response to normally painfu
and/or allodynia (pain in response to normally no
stimuli). Many patients with these conditions a
been shown to demonstrate more sensitivity to ma
uli other than pain (ie, auditory, visual), and dat
that these patients have a fundamental problem w
or sensory processing rather than an abnormality
to the specific body region in which the pain
experienced. In fact, the expanded relevance of
construct relates to the idea that all patients (w
without pain) have different “volume control” se
their pain and sensory processing. The position
bell-shaped curve of pain or sensory sensitivit
determines whether they will have pain or other
symptoms during the course of their lifetime a
severe these symptoms will be.
● In addition to pain and sensory amplification, oth
underlying mechanisms that have been identified
illnesses include: (1) neurogenic inflammation, e
of mucosal surfaces, leading to increasedmast cell
appearance of a mild inflammatory process in th
ery; (2) autonomic nervous system dysfunction
hypothalamic pituitary dysfunction.
● Similar types of therapies are efficacious for all
conditions, including both pharmacological (eg,
compounds such as amitriptyline) and nonpharm
cal treatments (eg, exercise and cognitive behavio
apy [CBT]). Conversely, patients with these co
typically do not respond to therapies that are
when pain is attributable to damage or inflamm
tissues (eg, nonsteroidal antiinflammatory drugs,
injections, surgical procedures).
The aforementioned list is meant to be a summa
findings across the functional somatic or central s
field. CFS is a heterogeneous disorder and likely
patients who have entirely different pathophysiology
those who have an infectious or metabolic condition
yet to be identified.
Some patients whomeet criteria for CFSmay not
spectrum of illness as the root cause for their symp
FINDINGS SPECIFIC TO CFS
Cognitive difficulties have been particularly well-st
CFS. The authors of CFS studies have suggested that
problems are a common complaint, but some author
that these subjective symptoms are accompanied by
abnormalities on neuropsychological testing. Howev
did not find good correlation between objective n
chological findings or biological markers, and sym
dyscognition [44-48].S,
ge-
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Some of this disparity likely occurred because
testing paradigms did not focus on areas that wer
quently shown to be most abnormal in CFS, such
mation processing speed, motor speed, working
and simple and complex attentional tasks [49].
recent studies [50-53], authors have used neuropsy
cal batteries tailored to the domains that appear to
impaired. These authors typically identified grou
ences between CFS and control patients. These effe
independent of and could be differentiated from
found in frequently comorbid disorders, such as de
where there is greater psychomotor slowing.
There is a considerable disparity between any
self-assessment of his or her cognitive function and t
cognitive function as measured by neuropsycholog
teries in patients with and without disease. The in
possible brain dysfunction in CFS also led to a
structural imaging studies in CFS. Many studies
abnormalities in the white matter on structural
resonance imaging scans, but the authors of seve
controlled studies [54-58] failed to replicate these
and none of the findings on magnetic resonance
were ever found to be sensitive or specific for CFS.
A newer method of assessing brain volumes ha
widespread use in neuroscience and chronic pain s
is just beginning to be applied to CFS. The authors o
study [59] have suggested that improvements after C
accompanied by increases in brain volume. By th
functional neuroimaging studies, researchers [60] a
examined changes in blood flow with activity-relat
and in CFS the provocation of fatigue has been a
with emotional responses that patients may have
suppressing.
Sleep has also been well-studied in CFS because
conclusion might be that chronic sleep deprivation
fatigue and other comorbid symptoms found in CFS
[61-63]. Many sleep abnormalities were noted in a
studies of CFS patients, but similar to findings
studies of FM patients, none of these findings was fou
sensitive or specific for FM or CFS [64]. Nonethe
becoming increasingly clear that there are very im
interrelationships between the symptoms of pain
and insomnia and the underlying pathogenesis
symptoms that are so often shared [64].
Exercise and activity level are as important as
CFS and the entire spectrum of illness. Couch
rarely develop CFS. Several reports document t
typically occurs in patients who had high premorb
of activity, and, in fact, high premorbid levels o
and a lower body mass in young adulthood w
strongest predictors of CFS later in life [27,65].
often report excellent preillness physical fitness
ergy and an abrupt onset of fatigue. After the
illness, patients indicate that physical exertion tends to
ted th
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420 Clauw CHRONIC FATIGUE SYNDROMEexacerbate the fatigue. Glass et al [66] demonstra
within a group of healthy, young subjects, the o
developed multiple somatic symptoms after expe
exercise cessation were those that had autono
immune profiles resembling those of CFS patients
studies performed by our group further exam
additive and synergistic roles that sleep restric
exercise cessation have on the development of
symptoms in healthy patients and demonstrated
ular exercise seems to buffer some of the adverse
sleep on symptom development. Female patien
much more likely to have somatic symptoms w
prived of either sleep or exercise.
Because of their frequent co-occurrence, psychi
psychological abnormalities have also been very wel
in CFS. With the advent of a better understandin
neurobiology of these illnesses, investigators w
staunchly viewed CFS as a psychiatric condition ha
icantly tempered their views, now acknowledging t
conditions are clearly separable from, and often occ
pendently of, psychiatric disorders [67,68]. As not
ously, both epidemiologic and twin studies have sh
CFS and other CSS are clearly separate from conditi
as anxiety and depression [39]. Patients with ps
conditions earlier in life have a 2 to 3 times greate
developing CFS than those who do not have pr
psychiatric diagnoses, but this still means that most
with CFS in the general population neither had o
diagnosable psychiatric condition [69].
Studies have not found personality disorders to
prevalent in people with CFS. This finding dispels
conception that these are type A individuals who
dissatisfied with their inability to perform tasks th
also cannot perform. More recent studies, however,
that a personality trait, neuroticism, was associa
more severe symptoms in those with CFS [69,70]. It
think of psychological and psychiatric symptoms sim
sleep or cognitive disturbances in CFS, that is, as a
that is important to evaluate in patients with CFS
abnormalities can often be identified. When these
bidities occur, they often add to the functional burd
illness, because depression in addition to CFS is lik
associated with disability and fatigue [71].
POTENTIAL UNDERLYING MECHANISM
CFS
Although the CSS conditions all were originally th
be autoimmune or inflammatory diseases, CFS
condition in which there are still a sizable nu
clinicians and investigators who believe that ong
fection and/or inflammation plays a significant
some patients.at
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The Role of Infections in Triggering C
and Related Syndromes
One of the reasons that CFS had long been consi
infectious disease is that it is very clear that this s
complex can be triggered by a variety of infections, i
the EBV, Q fever, and Lyme disease, among others [
recently, infections with unusual or newly discovere
gens such as the West Nile virus, severe acute re
syndrome (ie, SARS), and the H1N1 flu have all bee
to lead to the development of CFS [73-75].
A broader examination of the role of a variety of
in triggering this symptom complex helps put this
enon in perspective. Arguably the best set of studies
ing the underlying mechanisms that are operative i
fectious CFS are from a large longitudinal study in w
authors analyzed the long-term consequences of
with 3 different pathogens: the Ross River virus (the
epidemic polyarthritis), Coxiella burnetii (the cau
fever), and EBV and the development of CFS [76
prospective epidemiological study, patients expe
acute infection with these disparate pathogens
cruited, followed for 12 months, and monitored
development of fatigue, muscular pain, cognitive
tion, and mood disturbances. The symptom compl
oped in 12% of the patients at 12 months.
Although these infections cause markedly differ
presentations, a very stereotypical chronic syndrom
acterized by pain, fatigue, and memory difficulties)
at a remarkably similar rate after each infection
graphic, psychological, or microbiological factors d
acute infection did not predict the development of th
tom complex [77]. None of the psychiatric measu
assessed in this study, which included the prese
premorbid or intercurrent psychiatric disorder, the
cism score, and the locus of control score, was sign
predictive of the development of chronic symptoms
the studies of emotional stress triggering pain in the
tion, although distress per se did not predict the chro
symptoms after infection, the presence and severi
matic symptoms (ie, the degree of “somatization”) d
acute infection was closely correlated with the su
development of chronic fatigue (and pain).
The relationship between acute infection and the
ment of chronic regional pain and other somatic sy
has been noted in a number of other conditions r
FM. For example, in a meta-analysis summarizing th
of 8 different studies, Halvorson et al [78] noted tha
imately 10% of patients developed postinfectious IB
episode of acute infectious gastroenteritis, regardle
viral or bacterial pathogen that caused the acut
Similarly, an episode of acute urinary tract infectio
dent in a proportion of women who develop in
cystitis/painful bladder syndrome. In fact, in a recent study,
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421PM&R Vol. 2, Iss. 5, 2010Hamilton and associates [79], who were among th
investigate this issue across syndromes, found that
of gastroenteritis in diagnosed in primary care w
factors for IBS, whereas viral infections increased th
subsequent development of CFS. They again fo
premorbid psychiatric disorders such as depress
modestly increased the risk of this occurring.
These results imply that various forms of acute
are capable of triggering syndromes such as CFS
with multifocal or regional pain; chronic pain most
occurs in the body region initially affected by the i
There are often accompanying somatic symptoms
fatigue, memory, and mood difficulties. The risk
symptom complex occurring with various infection
sistently found to be approximately 5% to 10%. Th
for this consistency is not clear. Evidently, the inciti
tion must be of sufficient severity and duration bec
increase in occurrence of chronic symptoms is not
after common viral infections of short duration. Th
specificity regarding the triggering effect of infect
well be associated with an underlying genetic predis
activated in a similar manner by various pathogens,
patients with a set of “maladaptive” behavioral respo
could lead to symptoms, such as cessation of routine
or sleep.
At present, there is one active research area of i
tion focused on a potential infection that may be
CFS: the XMRV virus [80]. Although the study dem
ing both antibody and culture evidence of this virus
proportion of CFS patients was methodologically
albeit with very few controls, this field has “be
repeatedly. These results need to be replicated by
group because the institute that performed this st
ostensibly created to identify the infectious or imm
derpinnings to CFS, and then longitudinal studies
demonstrate causality rather than association, as
learned from previous studies in CFS.
Role of Cytokines
There is an expansive literature on this topic, with
thors of many studies identifying differences in
levels in CFS populations (usually in highly selecte
care patients) and others finding normal levels.
Klimas, and colleagues [81] have arguably been
active group studying subsets of CFS patients with
levels of cytokines, and they have shown that some b
cytokines are elevated in their cohort of CFS patie
pared with control patients. However, other grou
recently published studies in which there was superi
odology, including matching of case and control
such as with population-based approaches, or twin
These studies failed to find any specific differences
CFS patient and control subjects, but the population-basto
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studies do show that inflammation is a nonspecific fi
patients with “unwellness” and is also affected by co
such as obesity [5,82].
In addition, recent findings regarding the role of g
astrocytes, and other neural elements formerly unde
be support structures has led to a critical reexami
whether subtle inflammatory changes in the central
system may be responsible for some of the sympt
served in conditions such as FM. Immunological
have a role in the maintenance of central sensiti
chronic pain, which is enhanced through release
flammatory cytokines by central nervous system g
thus, the traditional paradigm of inflammatory versu
flammatory pain may gradually be understood as les
omous.
COULD CFS (IN PART) REPRESENT A
BIOLOGICALLY BASED PERCEPTUAL
AMPLIFICATION PROBLEM AS THE RES
OF AUGMENTED SENSORY PROCESSIN
As briefly discussed, a major pathophysiological find
related syndromes that share overlapping clinical an
genic features with CFS, such as FM, IBS, chronic h
and interstitial cystitis, is that these conditions are c
ized by hyperalgesia and allodynia, both on expe
pain testing as well as functional neuroimaging. The
of early studies typically used dolorimetry to assess
pain threshold and concluded that tenderness was
part related to psychological factors because these m
of pain threshold were correlated with levels of
[83-85].
To minimize the biases associated with “ascend
the individual knows that the pressure will be pr
increased) measures of pressure pain threshold, Pe
colleagues [86-89] performed a series of studies us
sophisticated paradigms, including random delivery
sures. These studies showed that: (1) the randomme
pressure pain threshold were not influenced by
distress of the individual, whereas tender point co
dolorimetry examinations were; (2) patients with
much more sensitive to pressure even when the
sophisticated paradigms were used; (3) patients
were not any more “expectant” or “hypervigilant” t
trol patients; and (4) pressure pain thresholds at any
in the body are highly correlated with the average te
at all 18 tender points and 4 “control points” (the th
and forehead).
In addition to the heightened sensitivity to pressu
in FM, other types of stimuli applied to the skin
judged as more painful or noxious by these patients
ing heat [88,90-92], cold [91,93], and electrical stim
These same findings of hyperalgesia and allodynia hed noted in most of the other conditions acknowledged to be
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422 Clauw CHRONIC FATIGUE SYNDROMEpart of this continuum, including CFS, IBS, TMJD
type headache, idiopathic low back pain, vulvody
interstitial cystitis [95-99]. Brain imaging studies a
onstrate the existence of central pain augmentatio
IBS, low back pain, and several other conditions [1
Finally, recent studies have suggested that FM a
chronic pain states are not just characterized by
sponsiveness to painful somatic or visceral stimuli
they also exhibit a “left-shift” in noxiousness or un
ness of other sensory experiences, such as the brig
light or loudness of auditory stimuli [103,104]. Ge
colleagues [105,106] used an identical random stair
adigm to test FM and CFS patients’ threshold to the
of auditory tones and to pressure. They found that a
of sensory sensitivity that combined stimulus:resp
sults for both pressure pain and auditory unpleasant
increased in both CFS and FM patients compared w
trols, was independent of psychiatric status, and was
correlated with symptoms as well as functional statu
CFS and FM patients.
The notion that FM and related syndromes mig
sent syndromes in which there is biological amplifi
all sensory stimuli has significant support from fu
imaging studies that suggest that the insula is on
most consistently affected regions. This region h
noted to play a critical role in sensory integration,
posterior insula serving a purer sensory role
anterior insula associated with the emotional proc
sensations [107-109].
Because self-report of both central and peripher
are determined on the basis of the patient’s “percept
conceivable that sensory amplification may be p
fundamental role in the pathogenesis of CFS and m
role in other fatigue states. No studies have directly
this hypothesis in CFS by demonstrating a similar “l
in many stimulus:response functions, but nearly a
that have examined the fatigue response to any singl
(eg, work performed on exercise or cognitive testi
noted a similar left-shift to what has been observedw
sensory experiences throughout this spectrum o
[25,110].
The Potential Role of Specific
Neurotransmitters
Overall, the analogy of an increased “volume co
“gain” setting on pain and sensory processing in co
such as FM and CFS is supported by studies from a v
sources and probably is largely responsible for the a
edged overlap between these conditions and “multip
ical sensitivity,” which is a misnomer because these
also experience a left-shift in noxious threshold
sensory stimuli. Similar to essential hypertension in
variety of root causes can lead to elevated systemic bloon
nd
m-
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pressure, these disorders may in part represent “
hypertension of pain and sensory processing pathw
In FM there has been extensive study of neurotran
levels that tend to be pronociceptive (ie, Figure 3
inhibit pain transmission (ie, Figure 3, right), hav
dency to increase the volume control. Drugs th
neurotransmitters on the left or augment activity of
the right will typically be found to be effective treat
least for a subset of patients with this spectrum of i
The arrows on Figure 3 indicate the directio
abnormalities in neurotransmitter levels (either in
brospinal fluid [CSF] or other parts of the brain) t
been identified to date in FM. As noted, in FM
evidence for increases in the CSF levels of Subs
glutamate, nerve growth factor, and brain-derived n
phic factor, and low levels of the metabolites of s
norepinephrine, and dopamine. Any of these could l
“increase in the volume control” and augmented
sensory processing [111-114]. The only neurotra
system that has been studied to date and not found
of line in a direction that would cause augmen
transmission is the endogenous opioid system. B
levels and brain activity by functional neuroimaging
to be augmented, not reduced (as would cause au
pain processing) in FM, whichmay be why opioider
do not work well to treat FM and related pain sy
[115,116].
It is of note that nearly all of these neurotransmi
are known to affect pain and sensory transmission
profound effects on energy level and alertness, sl
other related homeostatic functions. Therefore, it
conceivable that imbalances of neurotransmitters
neurotransmitters that are believed to be playing role
transmission may be similarly leading to central fat
sleep disturbances when these same imbalances
excitatory and inhibitory neurotransmitters occur
regions that control these functions in CFS.
Function of the Stress Systems in CFS
Related Conditions
Because of the fact that disparate “stressors” can tr
development of these conditions, the human stress
has been closely examined for a causative role. These
are mediated primarily by the activity of the cortic
releasing hormone nervous system located in the hy
mus and locus-ceruleus-norepinephrine/autonomic
system in the brain stem. Recent research suggest
though this system in humans has been highly
throughout history, the stress response may be ina
ately triggered by a wide assortment of everyday occ
that do not pose a real threat to survival, thus initi
cascade of physiologic responsesmore frequently thod tolerated [117]. The type of stress and the environment in
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423PM&R Vol. 2, Iss. 5, 2010which it occurs also have an impact on how t
response is expressed. It has been noted that v
accidents experience a greater frequency of FM and
cial pain than those who cause them, which is congru
animal studies showing that that the strongest phys
responses are triggered by events that are accompan
lack of control or support and thus viewed as per
inescapable or unavoidable [118]. In humans, daily
and personally relevant stressors seem to be more c
causing symptoms thanmajor catastrophic events th
personally impact the individual.
The authors of 2 studies performed in the Unit
just before and after the terrorist attacks of 9/11 poin
not all psychological stress is capable of triggering o
bating fatigue, pain, or other somatic symptoms. In o
performed by Raphael and colleagues [43], no diffe
fatigue, pain, or other somatic symptoms was seen
dents of New York and New Jersey who had been
before 9/11 and then just after the terrorist attack
+
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Washington, DC, region (near the Pentagon) during
time period, patients with FM had no worsening o
other somatic symptoms after the attacks compared
before the attack [42].
Recent reviews regarding the role that “stress
infections, physical trauma, emotional stress) or cata
events may have in triggering the development of C
or related conditions have identified several factors
be much more important than the intensity of the “
in predicting adverse health outcomes. Female gend
or expectation of chronicity, lack of control of the
intensity of the initial symptoms, and inactivity or
work after the stressor make it more likely to tr
development of pain, fatigue, or other somatic sy
[119]. Naturally occurring catastrophic events such
quakes, floods, or fires are much less likely to lead to
somatic symptoms than similarly stressful events
“human-made,” such as chemical spills, or wa
Being exposed to a multitude of stressors simulta
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424 Clauw CHRONIC FATIGUE SYNDROMElater somatic symptoms and or psychological s
Intensely stressful events can lead to permanent
in the activity of both mouse and human stress
systems [117,121].
This link between exposure to “stressors” and th
quent development of CFS and FM led to studies o
stress systems in this condition. These studies have
shown alterations of the hypothalamic-pituitary
(HPA) axis and the sympathetic nervous system in
related conditions [122-127]. Although these stud
note either hypo- or hyperactivity of both the HPA
sympathetic nervous system in patients with FM an
conditions, the precise abnormality varies from
study. Moreover, these studies only find “abnormal
autonomic function in a very small percentage of
and there is tremendous overlap between patients
trol patients in these studies.
The best recent studies of the HPA axis in CFS
continued support for enhanced glucocorticoid
feedback and/or a reduced central HPA axis drive i
of patients with CFS, but they point out a very im
confound in studying HPA function: early life stre
and others have shown that early life stress may
permanent changes in HPA functions in humans, an
studies have suggested that the presence or absence
life stress was a potent predictor of HPA function in b
and population-based studies [128,129]. Similar
have been noted with FM patients, demonstrating
presence or absence of early life stress influenced C
of corticotropin-releasing hormone more strongly
other factor [130]. Studies in FM suggest that HPA fu
related to levels of pain but not fatigue [131]. In f
findings in groups of patients with CFS have not be
to be related to levels of fatigue.
Changes in baseline function of the stress respo
may occur after a stressor earlier in life have been s
predict which symptom-free patients without chron
other somatic symptoms are more likely to devel
somatic symptoms. This has been noted both in pop
based studies and in experiments in which health
adults are deprived of regular sleep or exercise [66,
This theoretical link among stress, changes in s
activity, and subsequent susceptibility to develop f
other somatic symptoms or syndromes is also supp
studies demonstrating that patients with FM and
conditions may be more likely than nonaffected pa
have experienced physical or sexual abuse in c
[133-136]. This appears to profoundly influence H
tion in CFS, and recent studies in CFS have establis
early life stress is similarly a major determinant of th
mal HPA findings in a group of CFS patients versus
This pattern of HPA hyporesponsiveness was predi
lack of response to CBT, demonstrating the impo
identifying subsets of patients before treatment [128,137ae.
es
se
se-
an
lly
nal
nd
ten
nd
ted
to
or
ts,
n-
ide
ive
ps
ant
im
to
ent
rly
FS
gs
the
els
ny
is
PA
nd
hat
to
or
ese
n-
ng
xis
or
by
ted
to
od
c-
hat
or-
ls.
f a
of
Role of Autonomic Dysfunction
Heart rate variability at baseline, and with tilt tabl
has been evaluated in patients with CFS and FM as
gate measure of autonomic function. Findings ha
somewhat inconsistent, especially with tilt tabl
[138]. Some of these findings may be indicative of
ing a diathesis to stress, or a response to decondition
example, several experimental studies have shown t
ations in heart rate variability similar to those in CF
populations may actually represent a diathesis as a m
autonomic tone that places patients at risk for de
CFS, FM, or related illnesses [66,132,139], possib
fying patients at risk.
Also, a recent study showed that heart rate variab
normalized after exercise therapy, suggesting that
these findings may be an epiphenomenon caused in
deconditioning [140,141]. However, there clearly is
of patients with prominent autonomic dysfunctio
this spectrum of disorders, and the authors of a rece
[142] suggest that deconditioning plays a role, and a
individuals with low cardiac output. Recent stud
pointed out that some of this autonomic dysfunctio
due to deconditioning, and that in some individu
CFS this may be severe enough to lead to lead to low
output. Peripheral fatigue is likely to contribute to th
picture in these patients with CFS and FM.
It is likely that these neurobiological alterations a
with other syndromes known to be associated w
and/or autonomic function such as depression or
matic stress disorder. A model of susceptibility and
mental aspects of these disorders that takes into acco
genetics and personality as risk factors is illustrated
3. This recognizes the critical importance of str
resetting stress response systems, as well as othe
including (1) the role of behavioral adaptations
stressors such as cessation of routine exercise
whether an individual is in an environment charact
control or support.
Twin Studies in CFS
Twin studies have been very instructive in dete
key clinical features as well as estimations of the
genetics versus environmental factors. Kato and co
[39,143,144] have performed a series of studies b
very large Swedish twin registry and have determi
CFS, FM, IBS, and headache share key symptoms o
multifocal pain, insomnia, and memory difficulties
they can be clearly distinguishable from depress
anxiety. In aggregate, these studies suggest that
mately half the risk of developing these illnesses i
and the other half environmental.
A series of elegant twin studies performed by B
]. and colleagues [18,145-149] with identical twins discordant
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425PM&R Vol. 2, Iss. 5, 2010for CFS has generally shown very few objective diffe
coping strategies, sleep, and a number of other m
They have suggested that genetic factors may be p
more significant role in male than female patients w
illnesses, and the authors suggest that perceptual ab
ities in sensory symptom expression may represent
gest difference between affected and nonaffected tw
Similar Treatments Work for Many of
CSS Entities
There have been very few randomized controlled
drugs for CFS, but several drug and nondrug therap
been shown to be effective for nearly any of the fu
somatic or central sensitivity disorders, further re
that this may well be a large overlapping disorder ra
several separate ones. Among classes of drugs, su
data suggest that tricyclic compounds are effective
ing most of the conditions noted [150-152]. Newe
nin-norepinephrine reuptake inhibitors such as du
and tramadol have similarly been shown to be effecti
a broad range of these conditions [153], and inte
duloxetine had much earlier been shown to be h
treating the pain associated with depression, whic
surprising. The alpha-2-delta ligands such as pregab
gabapentin also are being shown to be efficacious i
range of these entities [154].
The overall average improvements in fatigue no
these classes of drugs in FM is not as great as the
improvements in pain, in part because fatigue is a
common adverse effect of all of these drugs, leadin
impressive overall effects. However, when patients
and CFS have a favorable clinical response to these
tions (generally noted in approximately one-third of
there is typically a global improvement in all sy
including fatigue as well as pain [154-156]. This ob
would support the notion that similar neurotransm
turbances can lead to many somatic symptoms, i
both pain and fatigue.
Figure 4 lists the classes of drugs and their lev
dence in FM. Those drugs with the greatest level of e
FM are also being shown to work in subsets of patie
CSS. More importantly, drugs such as duloxetine a
shown to be effective in conditions such as osteoarth
low back pain, demonstrating the these central mec
that are “front and center” in patients with syndrome
FM may be also playing prominent roles in conditio
tofore thought to be peripheral pain syndromes. H
we have known for some time that hyperalgesia and
tations of central factors, as well as various other ind
a wide range of “fibromyaglia-ness,” are present in co
such as osteoarthritis and low back pain.
Any one of these classes of drugs only works
approximately one-third of patients, a fact entirely consistin
es.
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with findings supporting the strongly genetic, but p
disorder. Thus, clinicians will need different treatm
different patients. Going back to the “essential hype
of pain processing pathway” analogy, just as we us
classes of drugs acting in different body system
different molecular targets to control hypertension
tients may respond very well to one class of antihyp
drug but not another, the same is true of CSS syn
Patients may only respond to one of these classes of
may often be in several classes of centrally acting a
(eg, a low dose of cyclobenzaprine at bedtime, preg
gabapentin either just at bedtime or twice daily, an
tonin-norepineprine reuptake inhibitor such as dulo
milnacipran during the day). However, our current
cological armamentarium is not nearly as well-deve
central pain as for essential hypertension, which is l
of the reasons that these syndromes are often still d
treat.
Figure 4 also points out that classes of drugs that
effective for “peripheral” pain as the result of da
inflammation in peripheral tissues, such as nonster
tiinflammatory drugs and opioids, are not effective a
in central pain states. There are even data sugges
administering opioids to patients with central pa
could worsen their pain by leading to opioid-induce
algesia, which could augment and worsen the bas
peragesia that may be playing a central pathogeni
these conditions.
Just as many pharmacological therapies work acr
most of these conditions, similarly, nonpharma
therapies such as education, exercise, and CBT h
demonstrated to be effective across nearly all of
conditions [157-159]. Both exercise and CBT ha
acceptance and are supported by RCTs in CFS.
When prescribing exercise in CFS, it is impo
realize that these patients are different than healthy o
physiological cost of walking is significantly greater
Modified from Goldenberg et al. JAMA. 2004;292:2388-95.
Strong
Evidence
■ Dual reuptake inhibitors such as 
■ Tricyclic compounds (amitriptyline, cyclobenzaprine)
■ SNRIs and NSRIs (milnacipran, duloxetine, venlafax
■ Anticonvulsants (e.g., pregabalin, gabapentin)
Modest
Evidence
■ Tramadol
■ Selective serotonin reuptake inhibitors (SSRIs)
■ Gamma hydroxybutyrate
■ Dopamine agonists
Weak
Evidence
■ Growth hormone, 5-hydroxytryptamine, tropisetron, 
S-adenosyl-L-methionine (SAMe)
No
Evidence
■ Opioids, corticosteroids, nonsteroidal anti-inflammator
benzodiazepine and nonbenzodiazepine hypnotics, gu
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426 Clauw CHRONIC FATIGUE SYNDROMEfor these greater energy demands for walking in th
CFS have yet to be fully elucidated, but research sug
physiological need for very slow, graded exercise pro
treat CFS and other related conditions [160,161]. L
colleagues have recently demonstrated that after m
exercise, CFS and CFS-FMS patients show enhan
expression for receptors detectingmuscle metabolite
sympathetic nervous system activation [162]. Thi
supports the need for a “start low, go slow” the
approach to exercise in CFS, especially because e
tions after overactivity are very common.
CONCLUSION
In the past few decades, our understanding of
evolved significantly, as has our understanding o
conditions. CFS is a condition that has strong b
underpinnings and shares pathogenic features and
to treatment with many other syndromes characte
clusters of multifocal pain, fatigue, and other somat
toms. A better understanding of the underlying mec
and most effective treatment for this spectrum of il
critical to support clinicians treating these very
conditions. There are clearly subsets of patients with
have differing underlying reasons for their sympto
current efforts are focused on identifying subsets th
preferentially respond to therapies directed at root
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